Bright Green is a pre-revenue, development-stage company building a federally licensed facility to grow and sell cannabis and other controlled substances for research and pharmaceutical use in the U.S. Unlike state-licensed cannabis operators, Bright Green holds a DEA registration to bulk manufacture cannabis — one of only eight companies with this authorization — which allows it to sell to DEA-registered research institutions and pharmaceutical companies, export internationally, and supply APIs for prescription drug production. Bright Green's core asset is a 70-acre property in Grants, New Mexico, which includes a 22-acre greenhouse under renovation. The company plans to eventually build two additional 57-acre greenhouses on adjacent optioned land. Beyond cannabis, Bright Green is pursuing a second DEA registration to manufacture Schedule I and II controlled substances including psilocybin, peyote, ibogaine, morphine, and oxycodone — a strategy it calls "Drugs Made in America," premised on reducing U.S. reliance on foreign API suppliers. Bright Green also plans to sell hemp-derived CBN and CBG isolates directly to consumers, which fall outside DEA jurisdiction under the 2018 Farm Bill. The company's intended business model is B2B supply of pharmaceutical-grade controlled substance APIs and plant material under supply contracts, though it has not yet completed any commercial harvests or generated meaningful revenue. Bright Green's core argument is that DEA registration is difficult to obtain, making it a structural barrier to entry that limits competition.